Treatment of COVID-19 Patients Post-Bariatric Surgery: Issues for Consideration.

COVID-19 bariatric surgery drug absorption pharmacotherapy

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
31 Aug 2020
Historique:
received: 24 08 2020
accepted: 31 08 2020
entrez: 4 9 2020
pubmed: 4 9 2020
medline: 4 9 2020
Statut: epublish

Résumé

As COVID-19 has been expanding rapidly around the world, the types of patients and their backgrounds vary. The substantially altered GI anatomy/physiology after bariatric surgery presents new challenges to the field of oral drug therapy. In this report we highlight issues for consideration when treating COVID-19 patients who previously underwent bariatric surgery and provide practical tools to allow optimal care of these patients. Post-bariatric absorption/pharmacokinetic changes may warrant dose adjustment, as well as the use of liquid oral dosage forms or parenteral routes of administration, if available. Realizing the potentially altered pharmacokinetics of various drugs after bariatric surgery is essential for providing optimal pharmacological therapy and overall patient care.

Identifiants

pubmed: 32878333
pii: jcm9092827
doi: 10.3390/jcm9092827
pmc: PMC7565829
pii:
doi:

Types de publication

Editorial

Langues

eng

Références

Lupus Sci Med. 2019 Jun 16;6(1):e000335
pubmed: 31275579
Antimicrob Agents Chemother. 2020 Mar 24;64(4):
pubmed: 32015045
Am J Clin Nutr. 2011 Oct;94(4):1004-11
pubmed: 21865332
J Clin Endocrinol Metab. 2015 Apr;100(4):1434-44
pubmed: 25603461
Obes Rev. 2016 Nov;17(11):1050-1066
pubmed: 27335140
Clin Infect Dis. 2020 Jun 29;:
pubmed: 32597466
Aliment Pharmacol Ther. 2014 Sep;40(6):582-609
pubmed: 25078533
Int J Infect Dis. 2020 Oct;99:307-309
pubmed: 32522597
Ann Pharmacother. 2014 Jun;48(6):816-9
pubmed: 24615629
J Clin Med. 2019 Nov 12;8(11):
pubmed: 31726725
J Int Assoc Provid AIDS Care. 2015 Mar-Apr;14(2):116-9
pubmed: 25361558
Surg Obes Relat Dis. 2017 Jul;13(7):1245-1247
pubmed: 28420586
Surg Obes Relat Dis. 2019 Feb;15(2):333-341
pubmed: 30704913
Int J Antimicrob Agents. 2020 Aug;56(2):106080
pubmed: 32634603
Clin Obes. 2020 Oct;10(5):e12383
pubmed: 32533634
Br J Clin Pharmacol. 2012 Nov;74(5):774-87
pubmed: 22463107
Obes Rev. 2020 May;21(5):e12988
pubmed: 32100411
J Nutr. 2000 May;130(5S Suppl):1374S-7S
pubmed: 10801946
AIDS. 2003 Jan 3;17(1):136-7
pubmed: 12478084
J Clin Med. 2020 May 17;9(5):
pubmed: 32429592
J Antimicrob Chemother. 2012 Sep;67(9):2203-6
pubmed: 22577100
Int J Antimicrob Agents. 2020 Aug;56(2):106077
pubmed: 32634602
Lancet. 2020 Jun 13;395(10240):1820
pubmed: 32511943
AIDS. 2018 Aug 24;32(13):1903-1905
pubmed: 30045058
Obes Surg. 2019 Feb;29(2):735-738
pubmed: 30448980
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204

Auteurs

Carmil Azran (C)

Clinical Pharmacy, Herzliya Medical Center, Herzliya 46140, Israel.

Daniel Porat (D)

Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 8410501, Israel.

Arik Dahan (A)

Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 8410501, Israel.

Dror Dicker (D)

Department of Internal Medicine D and Obesity Clinic, Hasharon Hospital-Rabin Medical Center, 7 Keren Kayemet St., Petah-Tikva 49100, Israel.

Classifications MeSH